One man's cancer in the lining of the brain shrank on a new drug
Original title: Durable Intracranial Response to Sacituzumab Tirumotecan in HER2-Negative Salivary Duct Carcinoma With High TROP2 Expression: A Case Report.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was tested in people. That is the most reliable kind of research we share.
This was seen in one patient, but it has not been tested in a trial yet.
The short version
In one man, a drug shrank cancer that had spread to the brain's lining.
What was studied. This report is about one 62-year-old man with a rare cancer of the spit glands. It had spread to the lining of his brain, and he got a drug called sacituzumab tirumotecan.
What they found. His largest tumor shrank from 33.6 mm to 15.3 mm. No new tumors showed up in his brain. The cancer in his brain stayed under control for about 9 months, and his side effects got better with care.
What this means, and what it doesn't
What it could mean: This drug may be worth testing in more people whose spit gland cancer has spread to the brain. Doctors still need to learn who it helps most.
What it doesn't mean: This is about just one person, not a study of many people. It is not about tumors that start in the brain. It is far from being normal care, and it is not a cure.
Source: PubMed, September 1, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.